Most Read Articles
4 days ago
The consumption of red and processed meats does not seem to affect the likelihood of symptom relapse among Crohn’s disease (CD) patients in relapse, reports a recent study.
Pearl Toh, 2 days ago
In addition to the known evils of maternal smoking during pregnancy on the son’s semen quality, prenatal exposure to paternal smoking can also be harmful, according to data from a large Danish National Birth Cohort (DNBC) presented at the ESHRE 2019 Meeting.
4 days ago
Treatment with metformin may improve whole-body and peripheral insulin resistance (IR) in youth who are overweight/obese with type 1 diabetes (T1D), according to a study.
2 days ago
Fluticasone, swallowed from a multidose inhaler, and oral viscous budesonide slurry have comparable efficacies as initial treatment for eosinophilic oesophagitis, a recent study has found.

Nivolumab response a positive indicator for long-term survival in NSCLC

Pearl Toh
03 May 2019

Patients with previously-treated non-small-cell lung cancer (NSCLC) who responded early to nivolumab at 6 months showed better long-term survival compared with responders to docetaxel, according to pooled analyses of CheckMate 017 and CheckMate 057 presented at the AACR 2019 Annual Meeting.

At 4 years, the overall survival (OS) rate for all patients who received nivolumab was 14 percent, a rate almost threefold higher than those treated with docetaxel (5 percent). [AACR 2019, abstract CT195]    

When the analyses were restricted to a subgroup of patients with partial response (PR) or complete response (CR) at 6 months, the survival benefit of nivolumab was even more pronounced over docetaxel (4-year OS rate, 58 percent vs 12 percent). 

“These analyses in a large population of patients with previously-treated advanced NSCLC show, for the first time, that response to nivolumab correlates to a survival benefit over many years,” said study co-investigator Dr Scott Antonia, director of the Duke Cancer Institute Center for Cancer Immunotherapy in Durham, North Carolina, US in a press release.

“These long-term survival outcomes are particularly interesting given that, historically, the average 5-year survival rate for this patient population is approximately 5 percent,” he continued.

The CheckMate 017 and CheckMate 057 are two phase III studies which randomized a total of 854 patients (median age ~62.5 years) with previously-treated advanced NSCLC in a 1:1 ratio to receive nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m2 every 3 weeks).

Analyses stratified by response status revealed that responders to nivolumab (CR/PR) at 6 months consistently had better OS vs patients with similar response status to docetaxel across year 1 (81 percent vs 62 percent), year 2 (63 percent vs 38 percent), year 3 (61 percent vs 26 percent), and year 4 (58 percent vs 12 percent).

Among patients with stable disease, the nivolumab arm also showed higher OS rates through to year 4 compared with the docetaxel arm (19 percent vs 2 percent).

Furthermore, patients in the nivolumab arm had a longer response duration than those in the docetaxel arm (median, 24 vs 6 months). 

There were no new safety signals during the long-term follow-up. Treatment-related adverse events (TRAEs) leading to discontinuation occurred in 8.7 percent of patients in the nivolumab arm, with skin reactions being the most commonly reported for immune-related TRAE (incidence rate, 38.6/100 person-years).

The results demonstrate that response to nivolumab confers a durable survival benefit over docetaxel even after disease progression, according to the researchers.

Consistent with the global CheckMate 017 and 057 studies, the phase III CheckMate 078 which enrolled a predominantly Chinese population (n=504, median age 60 years) also showed that OS was significantly longer with nivolumab than with docetaxel (median, 12.0 vs 9.6 months, hazard ratio, 0.68; p=0.0006) over a median follow-up of 10.4 months. [J Thorac Oncol 2019;14:867-875]

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
The consumption of red and processed meats does not seem to affect the likelihood of symptom relapse among Crohn’s disease (CD) patients in relapse, reports a recent study.
Pearl Toh, 2 days ago
In addition to the known evils of maternal smoking during pregnancy on the son’s semen quality, prenatal exposure to paternal smoking can also be harmful, according to data from a large Danish National Birth Cohort (DNBC) presented at the ESHRE 2019 Meeting.
4 days ago
Treatment with metformin may improve whole-body and peripheral insulin resistance (IR) in youth who are overweight/obese with type 1 diabetes (T1D), according to a study.
2 days ago
Fluticasone, swallowed from a multidose inhaler, and oral viscous budesonide slurry have comparable efficacies as initial treatment for eosinophilic oesophagitis, a recent study has found.